FDA Calendar for Spectrum Pharmaceuticals, Inc. (SPPI)

| Register (free)
Spectrum Pharmaceuticals, Inc. ( Spectrum) is a commercial stage biopharmaceutical company, engaged in developing and commercializing therapies with a focus primarily in the areas of hematology-oncology and urology. The Company’s product is apaziquone (formerly EOquin), which is in two Phase 3 clinical trials for non-muscle invasive bladder cancer under a collaboration with Allergan Inc. Another drug, ozarelix is in a Phase 2 clinical trial for benign prostatic hypertrophy (BPH). On December 15, 2008, Spectrum and Cell Therapeutics, Inc. (CTI) partnered to form a joint venture, RIT Oncology, LLC (RIT), to develop Zevalin ([90Y]-ibritumomab tiuxetan) in the United States. Its subsidiaries include OncoRx Pharma Private Limited, Spectrum Pharmaceuticals GmbH, RIT Oncology, LLC and Spectrum Pharma Canada. During the year ended December 31, 2008, the Company dissolved


Drug Pipeline

Drug NameType Of DrugFDA StatusDrug Phase
Zevalin Cancer ApprovedMarket
Fusilev Cancer Pending DecisionPhase 3
Belinostat Cancer UnknownPhase 2
EOquin (Apaziquone) Cancer UnknownPhase 3
Ortataxel Cancer UnknownPhase 2


Events

No future events listed at this time, please check back later.
5 past event(s) found. Click here to view them.

Add New Event

In order to write a comment you must first login.

Login or Register (for free!)

Add Event

SPPI

$14.35
0.15 +1.06%
2/3/2012 4:00:00 PM

Sponsors

Other Links